Originally published November 10 2004
Arthritis drug Bextra found to promote heart attacks and strokes
by Mike Adams, the Health Ranger, NaturalNews Editor
Following the recent revelations that Vioxx cause a high incidence of heart attacks and strokes, a competing drug from Pfizer, Bextra, has now been shown to display similar health problems. What's especially weighty about this particular revelation is that it comes from the American Heart Association, a disease-industry group that has traditionally acted in favor of pharmaceutical companies. Because of this, the AHA deserves credit for allowing this study to be published. In the preliminary results, Bextra was found to increase the incidence of heart attacks and strokes by 219%. The cardiologist who presented the study, Dr. Garret Fitzgerald, called Bextra, "A time bomb waiting to go off," and noted that the apparent dangers of Bextra exceed those associated with Vioxx.
Pfizer, of course, downplayed the study in an attempt to minimize any negative backlash from its release. The question remains, however: will Pfizer now follow in Merck's footsteps and voluntarily recall Bextra? And if it refuses to do so, will the FDA step in and finally perform the regulatory function it has been so reluctant to use by banning Bextra from the market? Or will this warning be swept aside in favor of a policy that allows this drug to continue to be sold to tens of millions of Americans, regardless of its questionable safety?
REVIEW TYPE
All content posted on this site is commentary or opinion and is protected under Free Speech. Truth Publishing LLC takes sole responsibility for all content. Truth Publishing sells no hard products and earns no money from the recommendation of products. NaturalNews.com is presented for educational and commentary purposes only and should not be construed as professional advice from any licensed practitioner. Truth Publishing assumes no responsibility for the use or misuse of this material. For the full terms of usage of this material, visit www.NaturalNews.com/terms.shtml